Articles
CSL plots its future course with R&D
To no one's surprise, CSL has become the dominant force in the Australian biotechnology sector. Graeme O'Neill learns from CSL's chief scientist, Andrew Cuthbertson, about the solid research that will drive the company in the next few years. [ + ]
Scientific advances boost anti-doping campaign
The unprecedented anti-doping campaign for the 2006 Commonwealth Games in Melbourne is aimed at making these Games the cleanest ever with thousands of tests being carried out on athletes in Australia and overseas
[ + ]Microscope allows the tracking of a functioning protein
A Stanford University research team has designed the first microscope sensitive enough to track the real-time motion of a single protein down to the level of its individual atoms
[ + ]Narhex boss sets out path to market
Sydney-based Narhex has begun recruiting for an early-stage trial of an HIV drug. Helen Schuller spoke with the company's MD, John Mills, about HIV drug development, working in China, and good management. [ + ]
Kidney stone analysis using FTIR spectrometry
A Kidney Stone Library & Analysis Kit has been developed to assist in the identification and characterisation of kidney stones by spectral analysis
[ + ]Differential cell sorting speeds sample preparation
Researchers at Sandia National Laboratories in California have developed an enhancement to a dielectrophoresis system that they say could revolutionise the way biological sample preparation is conducted
[ + ]A way around a problem
Biotechnology has provided a solution to the problem of how to get science to the market without compromising research, writes editor-in-chief Iain Scott. [ + ]
Facing up to commercial reality
The research community is becoming more sophisticated in the way they approach intellectual property and industry partnerships. Ruth Beran looks at how technology transfer has changed, where it is going and the challenges it faces. [ + ]
Big pharma's partnering plans
Pfizer's Peter Corr told the AusBiotech 2005 conference that big pharma and biotech are part of a delicate ecosystem -- and both have key roles to play. [ + ]
'Without partners, you are dead'
US venture capitalist Osagie Imasogie told AusBiotech 2005 that biotech companies need to get aggressive when it comes to finding opportunities. [ + ]
India opens the door to partners
Kiran Mazumdar-Shaw told AusBiotech 2005 about opportunities for Australian biotech to work with India. [ + ]
Agbiotech's field of opportunity
In many places in the world, 'biotechnology' only means agricultural biotech. The same can't be said in Australia, where GM technology is a dirty word. But could economics and technology force Australia to change its views on biotech crops to keep up with the rest of the world? [ + ]
INTERVIEW: Sir Gus's big picture view
Ruth Beran asked Sir Gustav Nossal about Australia's latest institute -- which just happens to bear his name. [ + ]
A new concept of genes
The FANTOM Consortium for Genome Exploration Research Group has published two milestone papers in the journal Science, which transform our understanding of the information content of the mammalian genome
[ + ]Transgenic livestock, by half measures
Manipulating the genome before fertilisation could prove more successful that current technique used in animal transgenesis, Graeme O'Neill reports. [ + ]